Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: A global propensity score matched retrospective cohort study - 19/06/24
, Allison Limmer, MD a, Peyton Harris, BS b, Dario Kivelevitch, MD a, cKey words : 5-alpha-reductase inhibitor, androgenetic alopecia, dutasteride, epidemiology, erectile dysfunction, finasteride, pharmacology, sexual dysfunction
| Funding sources: None. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Data accessible via TriNetX only contains anonymized information as per the deidentification standard defined by the US Health Insurance Portability and Accountability Act (HIPAA) in section §164,514(a). Given this study used only deidentified data and did not involve individually identifiable patient data, this study was exempt from institutional review board approval. |
Vol 91 - N° 1
P. 163-166 - luglio 2024 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
